Chagas Disease - A Pipeline Analysis Report
- Published: May 2018
- Pages: 70
- SKU: IRTNTR22386
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
This pipeline analysis report provides detailed insights into the drug development landscape of the development of drug for Chagas disease including molecules at pre-clinical, discovery, and other development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapies employed, preferred route of administration, therapeutic modality, targets for drugs under development, and mechanism of action.
Overview of the drug development pipeline for Chagas disease
Chagas disease is also known as American trypanosomiasis as it is caused by Tryopanosoma cruzi. It is a vector-borne disease and has two phases, i.e., acute phase and the chronic phase. A patient in chronic phase experiences cardiac and intestinal complications. Patients suffering from this condition experience symptoms such as diarrhea, enlarged lymph glands, and heart inflammation and meningoencephalitis.
Many organizations such as the World Health Organization and Drugs for Neglected Diseases initiatives (DNDi) are developing a low-cost drug for the treatment of Chagas disease by collaborating with various pharmaceutical companies. Technavio’s market research analysts have predicted that with the introduction of such medicines as one of the most promising approaches to treat Chagas disease, the Chagas disease treatment industry size will grow in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery development stage. For instance, sponsors such as Astellas Pharma developed Novel compound and Savant HWP developed 18-MC, which are under discovery development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I, phase II, and phase III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are in the pre-clinical stage.
Chagas disease treatment market value: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Chagas disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Bayer
- Eisai
- Kancera
Therapeutic assessment of the drug development pipeline for Chagas disease by preferred route of administration
- Oral
- Undisclosed
According to Chagas disease treatment market insights, the oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for Chagas disease by therapeutic modality
- Small molecule
- Vaccine
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for a Chagas disease are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for Chagas disease?
- What are the companies that are currently involved in the development of drug development molecules for Chagas disease?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
- US
- Europe
- China
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases

DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts

REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
